Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of QY211 Gel in Healthy Subjects and Atopic Dermatitis
NCT05843422Phase 1Unknown
- Sponsor
- E-nitiate
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QY211 in atopic dermatitis (AD) (7 arms), sponsored by E-nitiate. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Clinical Laboratory Abnormalities and 4 more. Status: unknown.
02
Drugs
QY211
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05843422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843422.